Drug Trial Radar · NCT00833300
Haloperidol vs Olanzapine for the Management of ICU Delirium
Last checked: Nov 20, 2026Latest source record: Aug 3, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
200
Planned (sponsor's estimate)
Start
Jun 2008
Primary completion
Nov 2011
Study completion Nov 2011
Sponsor
- Lead sponsor
- Richard HallAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Dalhousie University
- First posted
- Feb 2, 2009
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this randomized clinical trial is to determine whether haloperidol is superior to olanzapine for the treatment of ICU acquired delirium. The hypothesis is that haloperidol is in fact superior to olanzapine in treating ICU acquired delirium and sustaining delirium free time.
Conditions
- Delirium
- Agitation
Interventions
HaloperidolDrug
* 2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours. * Reassess in 24 hours. * Delirium absent - Continue dose for 24 hours then discontinue. * Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours. * Reassess in 24 hours. * Delirium absent - Continue dose for 24 hours then discontinue. * Delirium present - Discontinue current drug therapy and select one of: 1. Quetiapine up to 100 mg/day 2. Risperidone up to 6 mg/day 3. Loxapine up to 50 mg/day 4. Methotrimeprazine up to 75 mg/day * Reassess in 24 hours. * Delirium absent - Continue for 24 hours then discontinue. * Delirium present - Treatment at discretion of attending physician.
OlanzapineDrug
* 2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours. * Reassess in 24 hours. * Delirium absent - Continue dose for 24 hours then discontinue. * Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours. * Reassess in 24 hours. * Delirium absent - Continue dose for 24 hours then discontinue. * Delirium present - Discontinue current drug therapy and select one of: 1. Quetiapine up to 100 mg/day 2. Risperidone up to 6 mg/day 3. Loxapine up to 50 mg/day 4. Methotrimeprazine up to 75 mg/day * Reassess in 24 hours. * Delirium absent - Continue for 24 hours then discontinue. * Delirium present - Treatment at discretion of attending physician.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Resolution of delirium as indicated by an Intensive Care Delirium Screening Checklist score of less than 4Time frame: Every 24 hours
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Halifax Infirmary; Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
Victoria General Hospital; Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.